AF Form 1224: Blood Transfusion Reaction Investigation

AF Form 1224: Blood Transfusion Reaction Investigation – Blood transfusions save lives in military and civilian healthcare settings, but they carry a small risk of adverse reactions. When a suspected transfusion reaction occurs, rapid recognition, immediate action, and thorough documentation are essential for patient safety and regulatory compliance. In the U.S. Air Force, AF Form 1224 (Blood Transfusion Reaction Investigation) serves as the standardized tool for this critical process.

This article explains the purpose of AF Form 1224, how to use it step-by-step, the underlying procedures, and its importance within Air Force and broader U.S. transfusion medicine standards. It is intended for medical professionals, including transfusionists, laboratory technicians, pathologists, and healthcare providers working in Military Treatment Facilities (MTFs).

What Is AF Form 1224?

AF Form 1224, officially titled “Blood Transfusion Reaction Investigation,” is an Air Force Information Management Tool (IMT) form (revision 20040819 V1). It provides a structured, multi-section document to record the detection, initial response, clinical observations, laboratory investigation, and final evaluation of a suspected blood transfusion reaction.

The form ensures a consistent, traceable process that supports:

  • Immediate patient care decisions.
  • Identification of clerical, identification, or product-related errors.
  • Laboratory confirmation or rule-out of hemolysis, incompatibility, or other causes.
  • Compliance with Air Force Instructions and federal regulations.

Download the official form here: AF Form 1224 PDF

Note: Always use the most current version from the official Air Force e-Publishing site. Previous editions are obsolete.

When to Use AF Form 1224

Use AF Form 1224 whenever a possible transfusion reaction is suspected during or shortly after administration of any blood component (red blood cells, platelets, plasma, etc.). Common signs and symptoms that trigger investigation include:

  • Hives, itching, or flushing (allergic reactions).
  • Fever, chills, or rigors.
  • Shortness of breath, chest pain, or hypotension.
  • Headache, back/flank pain, or pain at the IV site.
  • Hemoglobinuria (dark urine), bleeding/oozing, or changes in vital signs (blood pressure or pulse).
  • Any unexpected clinical deterioration during transfusion.

Even mild symptoms warrant documentation and investigation to rule out serious causes such as acute hemolytic reactions, bacterial contamination, or transfusion-related acute lung injury (TRALI).

AFI 44-105 (Air Force Blood Program) explicitly directs the use of AF Form 1224 or an equivalent locally developed form for investigating suspected transfusion reactions.

Step-by-Step Process for Investigating a Suspected Transfusion Reaction

The form follows a logical sequence that aligns with best practices in transfusion medicine.

1. Initial Notification and Immediate Actions (Section I)

  • Stop the transfusion immediately and keep the IV line open with normal saline.
  • Check patient identification against the blood unit compatibility tag and SF 518 (Record of Transfusion).
  • Document and report any identification errors.
  • Notify the physician and the transfusion service (Blood Bank) with date/time.
  • Collect post-transfusion specimens (avoid hemolysis):
    • Lavender top tube (EDTA).
    • Red top tube (no anticoagulant).
    • Pink top tube if required locally.
  • Collect the first post-transfusion urine specimen (if available or by catheterization).
  • Complete transfusion documentation on SF 518, Section III.

2. Transfusionist Investigation (Section II)

Document:

  • Patient details (name, FMP/full SSN, primary diagnosis).
  • Blood product/unit number and amount transfused.
  • Observed signs/symptoms (check boxes for hives, itching, fever, chills, shortness of breath, etc.; specify pain location).
  • Additional details: medication allergies, use of infusion pump, blood warmer, multilumen catheter, IV solution manufacturer/lot number.
  • Transfusionist signature and date.

3. Laboratory Investigation (Section III)

  • Notify the Pathologist/Medical Director.
  • Perform a clerical review for discrepancies in labels, donor unit, SF 518, and compatibility tag.
  • Inspect the unit and IV tubing for abnormalities.
  • Check pre- and post-transfusion samples for hemolysis.
  • Perform Direct Antiglobulin Test (DAT) interpretation.
  • ABO/Rh confirmation on pre- and post-samples.
  • Urine occult blood test.
  • Technician performing the investigation should ideally differ from the person who did pre-transfusion testing.
  • Record results and notify the pathologist/provider of findings.

Send the completed form, blood bag with administration set, filter, IV fluids, and specimens to the transfusion service STAT.

4. Extended Laboratory Investigation (Section IV – As Needed)

Additional testing may include:

  • Antibody screen and crossmatch interpretation.
  • Gram stain and blood cultures (donor unit and patient).
  • Bilirubin and haptoglobin levels (pre- and post-transfusion).
  • Other tests as directed by the Medical Director or local operating instructions.

The Air Force Transfusion Medicine Consultant is available for guidance on complex cases.

5. Pathologist/Medical Director Evaluation

The pathologist reviews all findings, provides conclusions/comments, and signs off. Results are documented in the patient’s medical record (often via SF 513 Consultation Sheet).

Why Proper Use of AF Form 1224 Matters?

  • Patient Safety: Quick identification of hemolytic reactions, bacterial contamination, or other issues allows timely treatment (e.g., fluids, diuretics, supportive care) and prevents further harm.
  • Regulatory Compliance: The form supports FDA requirements for investigating adverse reactions (21 CFR 606.170). Fatalities related to transfusion must be reported to the FDA’s Center for Biologics Evaluation and Research (CBER) as soon as possible, with a written report within 7 days.
  • Quality Improvement: Thorough documentation helps identify systemic issues (clerical errors, process gaps) and supports hemovigilance efforts.
  • Legal and Accreditation: Accurate records protect the facility and align with AABB Standards for Blood Banks and Transfusion Services (current 35th edition effective 2026), which emphasize adverse event investigation and reporting.

In the broader U.S. context, transfusion services follow similar protocols, often using AABB’s Common Transfusion Reaction Reporting Form when communicating with blood suppliers.

Best Practices and Tips for U.S. Air Force Providers

  • Train all staff (nurses, transfusionists, lab techs) on immediate actions and form completion.
  • Maintain local operating instructions that complement AF Form 1224.
  • Ensure chain of custody for returned blood products and specimens.
  • For fatalities or serious events, coordinate with the facility’s transfusion safety officer and report per FDA and Air Force guidelines.
  • Review all reactions in transfusion committee meetings to drive continuous improvement.

Important: This article provides general guidance based on the official form and AFI 44-105. Always consult current Air Force instructions, your local Medical Treatment Facility policies, and the latest AABB/FDA standards for operational use. Clinical decisions should be made by licensed providers.

If you need the form, training resources, or assistance interpreting results, contact your facility’s Blood Bank or the Air Force Transfusion Medicine Consultant.

Keywords: AF Form 1224, blood transfusion reaction investigation, Air Force blood program, transfusion reaction protocol, AFI 44-105, SF 518, hemolytic reaction workup, military transfusion safety.

Last updated with sources current as of 2026. For the official downloadable form, visit the Air Force e-Publishing website.